Ozempic Copies For $14 As The Generic Glp-1 Era Starts In India

At slightest a twelve ample Indian drugmakers are group to rotation retired copies of Novo Nordisk A/S’s blockbuster weight-loss narcotics arsenic soon arsenic nan patent expires Friday, crashing prices successful nan state pinch nan third-largest overweight population.

Natco Pharma Ltd. plans to make an injection for semaglutide — nan progressive constituent successful some Ozempic and Wegovy — that will person a starting value of 1,290 rupees ($14) a month, connected nan first time nan generics are allowed. The pen instrumentality is expected to motorboat by April and costs astir 4,500 rupees a month, it said successful a filing.

By comparison, Novo’s Wegovy pen starts astatine astir 10,480 rupees ($113) successful India and astir $199 successful nan US nether nan self-pay model. Other companies are apt to value nan starting dose betwixt 3,000 rupees ($32) and 5,000 rupees a month, according to group acquainted pinch nan matter who did not want to beryllium named arsenic nan accusation is competitive.

While Canada was nan first to suffer patent protection for semaglutide successful January, nan Canadian wellness regulator hasn’t approved immoderate generics truthful acold efficaciously making India nan first awesome marketplace to spot a flood of copycat versions. The ensuing value warfare will beryllium intimately watched arsenic nan Danish drugmaker faces patent expiries successful cardinal markets including China, Brazil and Turkey.

Bloomberg News parsed institution filings and net telephone transcripts to place astatine slightest 12 ample drugmakers — Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd. and Lupin Ltd., among others — that person plans to waste generic semaglutide soon aft patent expiry. But nan existent standard of title will beryllium overmuch higher.

About 42 supplier manufacturers, including smaller ones, are expected to motorboat products nether much than 50 marque names this year, said Sheetal Sapale, a interrogator astatine marketplace information patient Pharmarack.

‘Case Study’

India is “an important case-study for nan future” nonaccomplishment of exclusivity connected this molecule, Jefferies analysts led by James Vane-Tempest wrote successful a Feb. 12 note. The brokerage estimates India’s weight-loss marketplace astatine astir $500 million, which “could emergence to $1 cardinal pinch nan correct pricing, take and authorities incentives.”

Demand for these weight-loss narcotics is besides precocious arsenic India’s 1.4-billion-plus organization faces a higher load of glucosuria and cardiovascular ailments, mostly owed to progressively sedentary municipality lifestyles. On nan different hand, high-calorie diets, dripping pinch lipid and fat, person led to a ample overweight organization that trails only nan US and China.

Generic drugmakers are besides experimenting pinch a scope of transportation formats, including single-use pre-filled syringes, single-shot pen injectors, vials, and reusable pens pinch adjustable dosing, nan group acquainted pinch nan matter said.

These are aimed astatine giving patients much flexibility, reducing nan costs load and making take of these anti-obesity therapies easier. Novo Nordisk’s Ozempic and Wegovy and Eli Lilly & Co.’s Mounjaro successful India presently travel successful a pre-filled pen pinch 4 shots.

The tweaked transportation methods tin besides build marque loyalty. If a diligent gets comfortable utilizing a peculiar device, they usually wouldn’t switch, Pharmarack’s Sapale said.

“The estimation of nan institution successful this therapy class arsenic good arsenic nan transportation strategy will beryllium nan differentiators now” since nan underlying semaglutide molecule is nan same, she added.

Indian drugmakers person besides started forging alliances. Zydus Lifesciences Ltd. this week announced a licensing business pinch Lupin and Torrent Pharma Ltd., while Eris Lifesciences Ltd. has tied up pinch Natco Pharma for nan trading of nan drug.

The generic drugmakers will besides attraction much connected smaller cities wherever innovator firms person not established a wide presence, Sapale said. “There will beryllium a batch of noise” successful nan marketplace arsenic firms conflict for share, she added.

Sanjay writes for Bloomberg.